This action will result in the purchase of 7,617 courses of zanamir (relenza) for the DHS medical countermeasures project. $17.37/course for a total of $132,307.29 for june 2018, for delivery no later…
Ended Awarded Last action
- Contract number
- 70RHAD18FR0000006
- Awardee
-
Glaxosmithkline, LLC UEI FRHTPHMZMX47
- Awarding agency
-
Office of Procurement Operations
Department of Homeland Security
- Obligated
- $132,307
Award facts
- Contract value 100% obligated
- $132,307.29 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- Countering Weapons of Mass Destruction Department of Homeland Security
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Not Competed Only One Source
- Pricing
- Firm Fixed Price
- Place of performance
- Perry Point, MD 21902, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | $0 | |
| Original award | $132,307 |
About this award
This federal contract award to Glaxosmithkline, LLC (doing business as Glaxosmithkline) is for the purchase of 7,617 courses of the antiviral medication Zanamir (Relenza) at a firm fixed price of $17.37 per course, totaling $132,307.29. The award is from the Department of Homeland Security Countering Weapons of Mass Destruction program, with delivery required by October 31, 2018. The contract does not have a set-aside designation. Glaxosmithkline is a pharmaceutical company that provides a range of products and services to U.S. government agencies, including influenza vaccines, antiviral medications, and other pharmaceutical goods. The company has held multiple indefinite delivery vehicle contracts with agencies such as the Department of Veterans Affairs, Centers for Disease Control and Prevention, and Defense Logistics Agency to support immunization programs and drug stockpiling initiatives.
Description
This action will result in the purchase of 7,617 courses of zanamir (relenza) for the DHS medical countermeasures project. $17.37/course for a total of $132,307.29 for june 2018, for delivery no later than october 31, 2018.
Quick answers
Who was awarded contract 70RHAD18FR0000006?
70RHAD18FR0000006 was awarded to Glaxosmithkline, LLC by Office of Procurement Operations (Department of Homeland Security) on September 6, 2018.
How much is contract 70RHAD18FR0000006 worth?
The government has obligated $132,307 on 70RHAD18FR0000006.
Which agency awarded contract 70RHAD18FR0000006?
Office of Procurement Operations (Department of Homeland Security) awarded 70RHAD18FR0000006, with funding from Countering Weapons of Mass Destruction (Department of Homeland Security).
Is contract 70RHAD18FR0000006 an order under another contract?
Yes. 70RHAD18FR0000006 is a delivery order under HSHQDC15D00016, an indefinite delivery contract.
Was contract 70RHAD18FR0000006 competed?
The extent of competition for 70RHAD18FR0000006 was not competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award